Overview

* Verastem Q3 2025 net product revenue reaches $11.2 mln, marking successful product launch

* Company reports Q3 net loss of $98.5 mln, reflecting increased operating expenses

* VS-7375 trial shows promising preliminary results in KRAS G12D mutant solid tumors

Outlook

* Verastem ( VSTM ) expects cash runway into the second half of 2026

* Company plans to report interim safety and efficacy update on VS-7375 in 1H 2026

* Verastem ( VSTM ) plans to engage with FDA for potential trials in PDAC and NSCLC in 1H 2026

Result Drivers

* R&D - The increase of $4.2 million, or 16.9%, was primarily related to increased drug substance and drug product costs, increased contract research organization costs, and increased investigator trial costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$98.51

Income mln

Q3 -$40.71

Income mln

from

Operatio

ns

Q3 $51.95

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Verastem Inc ( VSTM ) is $14.00, about 29.3% above its November 3 closing price of $9.90

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)